Key Takeaways
- A new at-home urine test may improve detection of aggressive prostate cancer biomarkers.
- The method is still in research and not a replacement for PSA testing.
- Larger clinical trials are needed before clinical use.
Urine Test
Prostate cancer is one of the most common cancers affecting males. If diagnosed in its early low-grade stages, the prognosis is excellent with a 99% 5-year survival rate. However, in the high-grade aggressive stages, prostate cancer has less than a 30% 5-year survival rate. Currently, the main method to screen for prostate cancer is by taking a blood sample and testing the presence of Prostate-Specific Antigen (PSA). However, although PSA has good sensitivity for prostate cancer, its specificity is relatively low. PSA may be elevated in other conditions affecting the prostate, such as infection or inflammation. False diagnosis of prostate cancer may lead to unnecessary invasive biopsy procedures, which are costly and painful to the patient.
Irish researchers have recently developed a promising method for urine-based prostate cancer detection that may offer advantages over the traditional PSA blood test. In Ireland alone, 3,500 new cases of prostate cancer are diagnosed every year, among which 500 men die from aggressive forms of the disease. This has led to many unnecessary invasive tests in people without prostate cancer.
The Research ‘epiCaPture’
- Researchers: Cancer researchers at University College Dublin (UCD)
- Objective: To study the development of a non-invasive test for prostate cancer using urine samples
- Participants: 500 adult men
- Methodology: Urine samples were collected and analyzed using a novel high-volume vacuum extraction method to detect prostate cancer–associated gene transcripts, including TMPRSS2:ERG, PCA3, and KLK3.
- Results: Early findings demonstrated that this method can improve the detection of cancer-related RNA transcripts in urine samples, especially those associated with aggressive prostate cancers.
The significance of the test
The improved detection of prostate cancer biomarkers in urine samples may help physicians determine which patients are most likely to benefit from further diagnostic procedures like biopsies. This could reduce the number of unnecessary invasive tests in men without clinically significant disease.
Furthermore, the test has the potential to detect aggressive prostate cancer in its early stages, allowing for timely and effective treatment. Prostate cancer can be treated by a combination of therapies that include surgery, chemotherapy, hormone therapy, and radiation.
If further clinical studies confirm the test’s accuracy and reliability, it may eventually be implemented as a screening tool for prostate cancer.
Related Reading:
Eating Mushrooms 3 Times a Week Can Lower Prostate Cancer Risk by up to 17%
Prostate Health: Foods and Supplements Men Should Take To Reduce Their Risk of Prostate Cancer
Bottom Line: Promising, But Not Yet Proven
While this urine-based test shows early potential, it’s important to emphasize that it is not yet a replacement for PSA screening. The current findings relate to improvements in RNA transcript detection, not confirmed diagnostic superiority. The study by University College Dublin was methodological, not a clinical trial comparing detection rates or outcomes.
There are still unanswered questions:
- How well does this method perform across diverse populations?
- Will it detect all forms of aggressive prostate cancer, or only those expressing certain biomarkers?
- Can it be reliably scaled, standardized, and covered by insurance systems?
Until large-scale clinical trials validate the test’s accuracy, specificity, and long-term predictive value, PSA testing will remain the standard. However, this research represents a valuable step toward less invasive, more precise screening — especially for men in active surveillance or reluctant to undergo repeat biopsies.
In short, this is not a revolution yet — but it’s a promising evolution.
FAQ: The Diagnostic Issues of Prostate Cancer
How is prostate cancer currently diagnosed?
The primary method is a blood test measuring Prostate-Specific Antigen (PSA) levels. If PSA is elevated, further tests, including biopsies, may be conducted.
What are the limitations of the PSA test?
PSA has high sensitivity but low specificity, meaning it can indicate prostate cancer when none is present due to benign conditions like infections or inflammation.
What happens if PSA levels are high?
Doctors may recommend additional tests such as a digital rectal exam (DRE), MRI, or a biopsy to confirm or rule out cancer.
Why are unnecessary biopsies a concern?
Biopsies are invasive, painful, expensive, and carry risks such as infection and bleeding. Many men undergo them unnecessarily due to false-positive PSA results.
What is the new urine test for prostate cancer?
Developed by University College Dublin researchers, this test uses urine samples collected at home to detect RNA transcripts specific to aggressive prostate cancer.
How does the urine test compare to PSA testing?
The test has demonstrated improved detection of prostate cancer–related transcripts in early trials. However, it has not yet been clinically validated as more sensitive or specific than PSA.
Why is a more specific test important?
A more specific test would reduce false positives, minimizing unnecessary biopsies and improving early detection of aggressive cancers.
Is the urine test already in use?
No, it is still in the research phase. If further studies confirm its effectiveness, it may become a widely used diagnostic tool in the future.
Could this test replace PSA screening?
Potentially, but not yet. It may initially be used alongside PSA testing to improve diagnostic accuracy.
How could the urine test improve prostate cancer diagnosis?
It could help doctors identify aggressive cancer earlier while avoiding unnecessary procedures for men without the disease.
When might this test become available for clinical use?
It depends on further research, clinical trials, and regulatory approval. It could take several years before widespread adoption.
How does early detection affect prostate cancer outcomes?
Early detection allows for timely treatment, which significantly improves survival rates, especially in aggressive cases.
What are the common treatment options for prostate cancer?
Treatment may involve surgery, radiation, hormone therapy, chemotherapy, or active surveillance, depending on the cancer’s stage and severity.
How common is prostate cancer?
It is one of the most common cancers in men. In Ireland alone, about 3,500 cases are diagnosed annually, with around 500 deaths.
Where can I get more information about prostate cancer screening?
Consult your doctor or visit trusted medical sources like the American Cancer Society or National Cancer Institute.
References
Webb, M., Manley, K., Olivan, M., Guldvik, I., Palczynska, M., Hurst, R., … Clark, J. (2019). Methodology for the At-home Collection of Urine Samples for Prostate Cancer Detection. BioTechniques, 68(2), 65–71. https://doi.org/10.2144/btn-2019-0092
FEEDBACK:
